Skip to content
10-Q

Quarterly Report

TScan Therapeutics, Inc. TCRX

0000950170-25-063968

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Long Term Debt Q1 2025 · Mar 31, 2025 $32.18M
Long Term Debt Q1 2025 · Dec 31, 2024 $32.07M
Current Liabilities Q1 2025 · Mar 31, 2025 $29.82M
Current Liabilities Q1 2025 · Dec 31, 2024 $35.96M
Total Liabilities Q1 2025 · Mar 31, 2025 $122.51M
Total Liabilities Q1 2025 · Dec 31, 2024 $130.15M
Current Assets Q1 2025 · Mar 31, 2025 $254.84M
Current Assets Q1 2025 · Dec 31, 2024 $292.72M
Total Assets Q1 2025 · Mar 31, 2025 $332.71M
Total Assets Q1 2025 · Dec 31, 2024 $371.12M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $178.69M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $140.51M
Shares Diluted Q1 2025 · Mar 31, 2024 94.88M sh
Capex Q1 2025 · Mar 31, 2024 $705K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$29.27M
Stockholders Equity Q1 2025 · Mar 31, 2024 $122.97M
Stockholders Equity Q1 2025 · Dec 31, 2023 $150.87M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.32
Eps Basic Q1 2025 · Mar 31, 2024 −$0.32
Sga Expense Q1 2025 · Mar 31, 2024 $7.08M
Rd Expense Q1 2025 · Mar 31, 2024 $24.86M
Net Income Q1 2025 · Mar 31, 2024 −$30.14M
Operating Income Q1 2025 · Mar 31, 2024 −$31.37M
Revenue Q1 2025 · Mar 31, 2024 $566K